Compare POM & AIMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | POM | AIMD |
|---|---|---|
| Founded | 2015 | 1984 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Other Specialty Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.3M | 11.5M |
| IPO Year | 2021 | 2008 |
| Metric | POM | AIMD |
|---|---|---|
| Price | $0.97 | $1.39 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 95.9K | 32.4K |
| Earning Date | 05-11-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $124,157.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 498.95 |
| 52 Week Low | $0.06 | $1.26 |
| 52 Week High | $6.43 | $4.44 |
| Indicator | POM | AIMD |
|---|---|---|
| Relative Strength Index (RSI) | 51.35 | 40.36 |
| Support Level | $0.17 | $1.33 |
| Resistance Level | $1.15 | $1.65 |
| Average True Range (ATR) | 0.13 | 0.11 |
| MACD | 0.01 | 0.01 |
| Stochastic Oscillator | 52.84 | 11.37 |
Pomdoctor Ltd is an online medical services platform for chronic diseases in China. With a focus on chronic disease management and pharmaceutical services, its business model forms a one-stop platform for medical services, which organically connects patients to doctors and pharmaceutical products. Its experience in tackling chronic diseases can be traced back to the launch of its platform on mobile devices. The company operates in two segments: Internet hospital, and Pharmaceutical supply chain. The majority of its revenue is derived from the Pharmaceutical supply chain segment.
Ainos Inc is a dual-platform company advancing artificial intelligence based smelltech technologies and immune therapeutics. Its primary strategic focus is the commercialization of its proprietary scent digitization platform, AI Nose, while the company also continue to develop therapeutic assets based on its low-dose oral interferon program, VELDONA. Its core technology platform, AI Nose, is an AI-based electronic olfaction system that integrates gas sensor arrays with proprietary artificial intelligence models, which it refers to as a smell language model (SLM), to digitize scent and volatile organic compound (VOC) signals into Smell ID, a machine-readable data format.